Influence of Inflammation-Based Prognostic Score on Mortality of Patients Undergoing Chemotherapy for Far Advanced or Recurrent Unresectable Colorectal Cancer
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 250 (2), 268-272
- https://doi.org/10.1097/sla.0b013e3181b16e24
Abstract
Background: Recent studies have revealed that the modified Glasgow Prognostic Score (mGPS), an inflammation-based prognostic score that includes only C-reactive protein (CRP) and albumin, is a useful tool for predicting postoperative outcome in cancer patients. However, few studies have investigated the mGPS in patients undergoing chemotherapy for far-advanced or recurrent unresectable colorectal cancer (AR-UCRC). Objective: To demonstrate the influence of the mGPS for prognostication of patients undergoing chemotherapy for AR-UCRC. Methods: The mGPS was calculated as follows: patients with an elevated level of CRP (>1.0 mg/dL) were allocated a mGPS of 1 or 2 depending on the absence or presence of hypoalbuminemia (P < 0.0001). Univariate analyses revealed that the neutrophil ratio (P = 0.0411), CA 19–9 (P = 0.0473), CRP (P = 0.0477), albumin (P = 0.0043), and mGPS (0, 1/2) (P < 0.0001) were associated with mortality. Multivariate analyses using these 5 factors revealed that only mGPS (0, 1/2) (odds ratio: 6.071; 95% CI: 1.625–22.68; P = 0.0073) was an independent risk factor of mortality. Conclusions: mGPS is an important and independent predictor of mortality in patients undergoing chemotherapy for AR-UCRC.Keywords
This publication has 31 references indexed in Scilit:
- Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 ChemotherapyJournal of Clinical Oncology, 2007
- C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinomaWorld Journal of Gastroenterology, 2006
- Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancerDiseases of the Esophagus, 2005
- C-Reactive Protein and the Risk of Incident Colorectal CancerJama-Journal Of The American Medical Association, 2004
- Elevation of preoperative serum C‐reactive protein level is related to poor prognosis in esophageal squamous cell carcinomaJournal of Surgical Oncology, 2003
- A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancerAnnals of Oncology, 2003
- Systemic inflammatory response predicts survival following curative resection of colorectal cancerBritish Journal of Surgery, 2003
- Measurement of the Systemic Inflammatory Response Predicts Cancer-Specific and Non-Cancer Survival in Patients With CancerNutrition and Cancer, 2001
- Preoperative Elevation of Serum C-Reactive Protein Is Related to Impaired Immunity in Patients With Colorectal CancerAmerican Journal of Clinical Oncology, 2000
- Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patientsCancer, 1996